UPDATE: Credit Suisse Initiates Spectrum Pharmaceuticals at Neutral; Lacking Fusilev Visibility

Loading...
Loading...
Credit Suisse initiated coverage on Spectrum Pharmaceuticals, Inc.
SPPI
with a Neutral rating and a $15.00 price target. Credit Suisse said, "SPPI is successfully building an oncology-specific, multiproduct company, with a strong focus on sustained profitability and returning value to shareholders. In H1:13, investors will be primarily focused on Fusilev sales and the impact of increased competition from generic leucovorin. Sales of Fusilev may decrease from 2012 highs and limit near-term stock performance. We prefer to take a wait-and-see approach and would look to buy SPPI with greater visibility on Fusilev. From a valuation perspective, we think that shares already reflect a reduction in Fusilev though consensus sales estimates remain high for 2013." Spectrum Pharmaceuticals closed at $12.67 on Monday.
Posted In: Analyst ColorInitiationIntraday UpdateAnalyst RatingsCredit Suisse
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...